In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods

Journal of Clinical Microbiology

Volumn 47, Issue 10, 2009, Pages 3170-3177

  Diekema, D J ^a   Messer, S A ^a   Boyken, L B ^a   Hollis, R J ^a   Kroeger, J ^a   Tendolkar, S ^a   Pfaller, M A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS;

EID: 70349648602     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00942-09     Document Type: Article

References (112)

1. Agarwal, S., K. Thakur, A. Kanga, G. Singh, and P. Gupta. 2008. Catheter-related candidemia caused by Candida lipolytica in a child with tubercular meningitis. Indian J. Pathol. Microbiol. 51:298-300.
2. Alter, S. J., and J. Farley. 1994. Development of Hansenula anomala infection in a child receiving fluconazole therapy. Pediatr. Infect. Dis. J. 13:158-159.
3. Antoniadou, A., H. A. Torres, R. E. Lewis, J. Thornby, G. P. Bodey, J. P. Tarrand, X. Y. Han, K. V. Rolston, A. Safdar, I. I. Raad, and D. P. Kontoyiannis. 2003. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 82:309-321. (Pubitemid 37229466)
4. Arago, P. A., I. C. Oshiro, E. I. Mannique, et al. 2001. Pichia anomola outbreak in a nursery: exogenous sources? Pediatr. Infect. Dis. J. 20:843-848.
5. Arevalo, M. P., A. J. Carrillo-Munoz, J. Salgado, D. Cardenes, S. Brio, G. Quindos, and A. Espinel-Ingroff. 2003. Antifungal activity of the echinocandin anidulafungin (VER 002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. 51:163-166.
6. Atkinson, B. J., R. E. Lewis, and D. P. Kontoyiannis. 2008. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med. Mycol. 46:541-546.
7. Bakir, M., N. Cerikcioglu, A. Tirtir, et al. 2004. Pichia anomala fungemia in immunocompromised children. Mycoses 47:231-235.
8. Barchiesi, F., A. M. Tortorano, L. F. DiFrancesco, M. Cogliati, G. Scalise, and M. A. Vivioni. 1999. In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J. Antimicrob. Chemother. 43:295-299. (Pubitemid 29082458)
9. Belet, N., E. Ciftci, E. Ince, N. Dalgic, S. Oncel, H. Guriz, A. Yagmurlu, H. Dindar, and U. Dogru. 2006. Caspofungin treatment in two infants with persistent fungemia due to Candida lipolytica. Scand. J. Infect. Dis. 38:559-562.
10. Blinkhorn, R. J., D. Adelstein, and P. J. Spagnuolo. 1989. Emergence of a new opportunistic pathogen, Candida lusitaniae. J. Clin. Microbiol. 27:236-240.
11. Carrasco, L., M. Ramos, R. Galisteo, D. Pisa, M. Fresno, and M. E. Gonzalez. 2005. Isolation of Candida famata from a patient with acute zonal occult outer retinopathy. J. Clin. Microbiol. 43:635-640.
12. Carrega, G., G. Riccio, L. Santoriello, M. Pasqualini, and R. Pellicci. 1997. Candida famata fungemia in a surgical patient successfully treated with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 16:698-699.
13. Chakrabarti, A., K. Singh, A. Narang, S. Singhi, R. Batra, K. L. N. Rao, P. Ray, S. Gopalan, S. Das, V. Gupta, A. K. Gupta, S. M. Bose, and M. M. McNeil. 2001. Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in northern India. J. Clin. Microbiol. 39:1702-1706.
14. Cheng, M. F., K. W. Yu, R. B. Tang, Y. H. Fan, Y. L. Yang, K. S. Hsieh, M. Ho, and H. J. Lo. 2004. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 48:33-37.
15. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Informational supplement, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Coleman, D. C., D. J. Sullivan, D. E. Bennett, G. P. Morgan, H. J. Barry, and D. B. Shanley. 1997. Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 11:557-567.
18. Collin, B., C. J. Clancy, and M. H. Nguyen. 1999. Antifungal resistance in non-albicans Candida species. Drug Resist. Updat. 2:9-14.
19. Colombo, A. L., M. Nucci, R. Salomano, M. L. M. Branchini, R. Richtmann, A. Derossi, and S. B. Wey. 1999. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn. Microbiol. Infect. Dis. 34:281-286.
20. Colombo, A. L., A. S. A. Melo, R. F. C. Rosas, R. Salomano, M. Briones, R. J. Hollis, S. A. Messer, and M. A. Pfaller. 2003. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B. Diagn. Microbiol. Infect. Dis. 46:253-257.
21. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
22. da Matta, V. L. R., M. de Souza Carvalho Melhem, A. L. Colombo, M. L. Moretti, L. Rodero, G. M. Duboc de Almeida, M. dos Anjos Martins, S. F. Costa, M. B. G. Souza Dias, M. Nucci, and A. S. Levin. 2007. Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. Antimicrob. Agents Chemother. 51:1573-1576.
23. D'Antonio, F. Romano, E. Pontieri, G. Fioritoni, C. Caracciolo, S. Bianchini, P. Olioso, T. Staniscia, R. Sferra, S. Boccia, A. Vetuschi, G. Federico, E. Gaudio, and G. Carruba. 2002. Catheter-related candidemia caused by Candida lipolytica in a patient receiving allogeneic bone marrow transplantation. J. Clin. Microbiol. 40:1381-1386.
24. Dick, J. D., R. P. Rosegard, W. G. Merz, R. K. Stuart, G. M. Hutchins, and R. Saral. 1985. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann. Intern. Med. 102:67-68.
25. Dimopoulos, G., A. Velegraki, and M. E. Falagas. 2009. A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. Antimicrob. Agents Chemother. 53:1242-1244.
26. Dube, M. P., P. N. Heseltine, M. G. Rinaldi, S. Evans, and B. Zawacki. 1994. Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin. Infect. Dis. 18:77-82.
27. Girmenia, C., G. Pizzarelli, F. Cristini, F. Barchiesi, E. Spreghini, G. Scalise, and P. Martino. 2006. Candida guilliermondii fungemia in patients with hematologic malignances. J. Clin. Microbiol. 44:2458-2464.
28. Hadfield, T. L., M. B. Smith, R. E. Winn, M. G. Rinaldi, and C. Guerra. 1987. Mycoses caused by Candida lusitaniae. Rev. Infect. Dis. 9:1006-1012.
29. Haron, E., E. Anaisse, F. Dumphy, K. McCredie, and V. Fainstein. 1988. Hansenula anomala fungemia. Rev. Infect. Dis. 10:1182-1186.
30. Hawkins, J. L., and L. M. Baddour. 2003. Candida lusitaniae infections in the era of fluconazole availability. Clin. Infect. Dis. 36:e14-e18.
31. Hazen, K. C. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev. 8:462-478.
32. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
33. Hiraski, S., T. Ljichi, N. Fujita, et al. 1992. Fungemia caused by Hansenula anomala: successful treatment with fluconazole. Intern. Med. 31:622-624.
34. Holzschu, D. L., H. L. Presley, M. Miranda, and H. J. Phaff. 1979. Identification of Candida lusitaniae as an opportunistic yeast in humans. J. Clin. Microbiol. 10:202-205.
35. Jones, R. N. 2000. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. J. Antimicrob. Chemother. 46(Suppl. T2):1-8.
36. Kabbara, N., C. Lacroix, R. P. de Latour, G. Socie, M. Ghannoum, and P. Ribaud. 2008. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 93:639-640.
37. Kalenic, S., M. Jandrlic, V. Vegar, et al. 2001. Hansenula anomala outbreak at a surgical intensive care unit: a search for risk factors. Eur. J. Epidemiol. 17:491-496.
38. Kao, A. S., M. E. Brandt, W. R. Pruitt, L. A. Conn, B. A. Perkins, D. S. Stephens, W. S. Baughman, A. L. Reingold, G. A. Rothrock, M. A. Pfaller, R. W. Pinner, and R. A. Hajjeh. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170.
39. Krcmery, V., S. Grausova, M. Mraz, E. Pichova, and L. Jurga. 1999. Candida guilliermondii fungemia in cancer patients: report of three cases. J. Infect. Chemother. 5:58-59.
40. Krcmery, V., and A. J. Barnes. 2002. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50:243-260.
41. Kurtzman, C. P. 1998. Yarrowia van de Walt and von Arx. Descriptions of teleomorphic ascomycetous genera and species, p. 420-421. In C. P. Kurtzman and J. W. Fell (ed.), The yeasts: a taxonomic study, 4th revised ed. Elsevier Science, Amsterdam, The Netherlands.
42. Listemann, H., K. D. Schulz, R. Wasmuth, F. Begemann, and W. Meigel. 1998. Oesophagitis caused by Candida kefyr. Mycoses 41:343-344.
43. Lockhart, S. R., S. A. Messer, M. A. Pfaller, and D. J. Diekema. 2008. Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J. Clin. Microbiol. 46:374-376.
44. Lockhart, S. R., S. A. Messer, M. A. Pfaller, and D. J. Diekema. 2008. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46:2659-2664.
45. Lockhart, S. R., S. A. Messer, M. A. Pfaller, and D. J. Diekema. 2009. Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J. Clin. Microbiol. 47:242-244.
46. Lockhart, S. R., S. A. Messer, M. Gherna, J. A. Bishop, W. G. Merz, M. A. Pfaller, and D. J. Diekema. 2009. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J. Clin. Microbiol. 47:1216-1217.
47. Ma, J. S., P. Y. Chen, C. H. Chen, and C. S. Chi. 2000. Neonatal fungemia caused by Hansenula anomala: a case report. J. Microbiol. Immunol. Infect. 33:267-270.
48. Mardani, M., H. A. Hanna, E. Girgawy, and I. Raad. 2000. Nosocomial Candida guilliermondii fungemia in cancer patients. Infect. Control Hosp. Epidemiol. 21:336-337.
49. Masala, L., R. Luzzati, L. Maccacaro, L. Antozzi, E. Concia, and R. Fontana. 2003. Nosocomial cluster of Candida guilliermondii fungemia in surgical patients. Eur. J. Clin. Microbiol. Infect. Dis. 22:686-688.
50. McClenny, N. B., H. Fei, E. J. Baron, A. C. Gales, A. Houston, R. J. Hollis, and M. A. Pfaller. 2002. Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob. Agents Chemother. 46:1325-1328.
51. Medeiros, E. A. S., T. J. Lott, A. L. Colombo, P. Godoy, A. P. Coutinho, M. S. Braga, M. Nucci, and M. E. Brandt. 2007. Evidence for a pseudo-outbreak of Candida guilliermondii fungemia in a university hospital in Brazil. J. Clin. Microbiol. 45:942-947.
52. Meis, J. F. G. M., M. Ruhnke, B. E. De Pauw, F. C. Odds, W. Siegert, and P. E. Verweij. 1999. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg. Infect. Dis. 5:150-153.
53. Merz, W. G. 1984. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J. Clin. Microbiol. 20:1194-1195.
54. Mestroni, S. C., and A. L. Bava. 2003. Hansenula anomala fungemia. Rev. Argent. Microbiol. 35:54-56.
55. Miller, N. S., J. D. Dick, and W. G. Merz. 2006. Phenotypic switching in Candida lusitaniae on copper sulfate indicator agar: association with amphotericin B resistance and filamentation. J. Clin. Microbiol. 44:1536-1539.
56. Minari, A., R. Hochem, and I. Raad. 2001. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin. Infect. Dis. 32:186-190.
57. Mok, W. Y., and M. S. Barreto da Silva. 1984. Mycoflora of human dermal surfaces. Can. J. Microbiol. 30:1205-1209.
58. Morgan, P., D. Sandlard, M. Donnelly, B. Shanley, J. Sullivan, and C. Coleman. 1996. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 42:1819-1830.
59. Murphy, N., C. R. Buchanan, V. Damjanovic, et al. 1986. Infection and colonization of neonates by Hansenula anomala. Lancet 1:291-293.
60. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, et al. 1996. The changing face of candidemia emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
61. Ninin, E., O. Morin, L. E. Tortorec, N. Milpied, P. Moreau, and J. L. Harousseau. 1997. Infection invasive á Candida lipolytica après allogreffe de moelle osseuse. J. Mycol. Med. 7:212-214.
62. Nitzulescu, V., and M. Niculescu. 1976. Three cases of ocular candidiasis caused by Candida lipolytica. Arch. Roum. Pathol. Exp. Microbiol. 35:269-272.
63. Nucci, M., and K. A. Marr. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41:521-526.
64. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
65. Pappagianis, H. D., M. S. Collins, R. Hector, and J. Remington. 1979. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob. Agents Chemother. 16:123-126.
66. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
67. Pasqualotto, A. C., T. C. T. Sukiennik, L. C. Severo, C. S. de Amorim, and A. L. Colombo. 2005. An outbreak of Pichia anomala fungemia in a Brazilian pediatric intensive care unit. Infect. Control Hosp. Epidemiol. 26:553-558.
68. Pasqualotto, A. C., A. G. Antunes, and L. C. Severo. 2006. Candida guilliermondii as the aetiology of candidosis. Rev. Inst. Med. Trop. Sao Paulo 48:123-127.
69. Paula, C. R., V. L. J. Krebs, M. E. Aaler, et al. 2006. Nosocomial infection in newborns by Pichia anomala in a Brazilian intensive care unit. Med. Mycol. 44:479-484.
70. Peman, J., M. Bosch, E. Canton, A. Viades, I. Jarque, M. Gomez-Garcia, J. M. Garcia-Martinez, and M. Gobernado. 2008. Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period. Diagn. Microbiol. Infect. Dis. 60:109-112.
71. Peyron, F., A. Favel, A. Michel-Ngugen, M. Gilly, P. Regli, and A. Bolmstrom. 2001. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J. Clin. Microbiol. 39:339-342.
72. Pfaller, M. A., S. A. Messer, and R. J. Hollis. 1994. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn. Microbiol. Infect. Dis. 20:127-133.
73. Pfaller, M. A., S. A. Messer, and A. Bolstrom. 1998. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn. Microbiol. Infect. Dis. 32:223-227.
74. Pfaller, M. A., S. A. Messer, S. Gee, S. Joly, C. Pujol, D. J. Sullivan, D. C. Coleman, and D. R. Soll. 1999. In vitro susceptibility of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37:870-872.
75. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, R. N. Jones, and the International Fungal Surveillance Participant Group. 2003. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J. Clin. Microbiol. 41:78-83.
76. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, and R. N. Jones. 2004. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. 48:101-105.
77. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
78. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
79. Pfaller, M. A., D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S. C. Cheng, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group. 2006. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol. 44:3551-3556.
80. Pfaller, M. A., D. J. Diekema, A. L. Colombo, C. Kibbler, K. Peng, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group. 2006. Candida rugosa, an emerging pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol. 44:3578-3582.
81. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
82. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
83. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
84. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, J. F. Meis, I. M. Gould, W. Fu, A. L. Colombo, E. Rodriguez-Noriega, and the Global Antifungal Surveillance Group. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745.
85. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
86. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
87. Quindos, G., F. Cabrera, M. del Carmen Arilla, A. Burgos, R. Ortiz-Vigon, J. C. Canon, and J. Ponton. 1994. Fatal Candida famata peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis who was treated with fluconazole. Clin. Infect. Dis. 18:658-660.
88. Reuter, C. W. M., M. A. Morgan, F. C. Bonge, F. Gunzer, M. Eder, B. Hertenstein, and A. Ganser. 2005. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin. Infect. Dis. 41:1365-1366.
89. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
90. Roostita, R., and G. H. Fleet. 1996. The occurrence and growth of yeasts in Camembert and blue-veined cheese. Int. J. Food Microbiol. 28:393-404.
91. Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
92. Sendid, B., C. Lacroix, and M. E. Bougnoux. 2006. Is Candida kefyr an emerging pathogen in patients with oncohematological diseases? Clin. Infect. Dis. 43:666-667.
93. Shin, J. H., D. H. Kook, D. H. Shin, T. J. Hwong, M. Kim, and S. P. Suh. 2000. Nosocomial cluster of Candida lipolytica fungemia in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 19:344-349.
94. Sobel, J. D. 2007. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr. Fungal Infect. Rep. 1:42-48.
95. Spanakis, E. K., G. Aperis, and E. Mylonakis. 2006. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43:1060-1068.
96. Spellberg, B. J., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
97. St. Germain, G., and M. Laverdiere. 1986. Torulopsis candida, a new opportunistic pathogen. J. Clin. Microbiol. 24:884-885.
98. Sugar, A. M., and D. A. Stevens. 1985. Candida rugosa in immunocompromised cancer patients. Case reports, drug susceptibility and review of the literature. Cancer 56:318-320.
99. Sullivan, D., and D. Coleman. 1997. Candida dubliniensis: an emerging opportunistic pathogen. Curr. Top. Med. Mycol. 8:15-25.
100. Sullivan, D. J., T. J. Westerneng, K. A. Haynes, D. E. Bennett, and D. C. Coleman. 1995. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidiasis in HIV-infected individuals. Microbiology 141:1507-1521.
101. Tavanti, A., A. D. Davidson, N. A. Gow, M. C. Maiden, and F. C. Odds. 2005. Candida orthopsilosis and Candida meapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43:284-292.
102. Thuler, L. C., S. Faivichenco, E. Velasco, et al. 1997. Fungemia caused by Hansenula anomala: an outbreak in a cancer hospital. Mycoses 40:193-196.
103. Tietz, H. J., V. Czaika, and W. Sterry. 1999. Case report: osteomyelitis caused by high resistant Candida guilliermondii. Mycoses 42:577-580.
104. Utley, J. R., J. Mills, J. C. Hutchinson, L. H. Edmunds, Jr., R. G. Sanderson, and B. B. Roe. 1973. Valve replacement for bacterial and fungal endocarditis. A comparative study. Circulation 48(1 Suppl.):III42-III47.
105. Vazquez, J. A., T. Lundstrom, L. Dembry, P. Chandrasekar, D. Boikov, M. B. Parri, and M. J. Zervos. 1995. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Bone Marrow Transplant. 16:849-853.
106. Wagner, D., A. Sander, H. Bertz, J. Finke, and W. V. Kern. 2005. Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving lipsomal amphotericin B and caspofungin for suspected aspergillosis. Infection 33:397-400.
107. Walsh, T. J., I. F. Salkin, D. M. Dixon, and N. J. Hurd. 1989. Clinical, microbiological, and experimental animal studies of Candida lipolytica. J. Clin. Microbiol. 27:927-931.
108. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522.
109. Wehrspann, P., and U. Fullbrandt. 1985. Report of a case of Yarrowia lipolytica (Wickerham et al.) van der Walt and von Arx isolated from a blood culture. Mykosen 28:217-222.
110. Wong, B., T. E. Kiehn, F. Edwards, E. M. Bernard, R. C. Marcove, E. de Harven, and D. Armstrong. 1982. Bone infection caused by Debaryomyces hansenii in a normal host: a case report. J. Clin. Microbiol. 16:545-548.
111. Yamada, S., T. Maruoka, K. Nagai, et al. 1995. Catheter-related infections caused by Hansenula anomala in children. Scand. J. Infect. Dis. 27:85-87.
112. Yoon, S. A., J. A. Vazquez, P. E. Steffan, et al. 1999. High-frequency in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob. Agents Chemother. 43:836-845.